Capricor Therapeutics, Inc. (NASDAQ: CAPR) is focused on discovering, developing and marketing first-in-class therapeutics for the treatment of diseases. Presently, the company is positioned at the forefront of one of the largest segments of the U.S. healthcare industry:  heart disease. Capricor’s lead product candidates currently target the prevention and treatment of heart failure and heart attacks, which make up a substantial portion of the estimated total annual costs of heart disease in the U.S. (over $200 billion). For more information, visit the company’s website at www.capricor.com.